Alembic Limited
NSE: ALEMBICLTD BSE: ALEMBICLTD
NSE
91.80
-0.67 (-0.72%)
Prev Close
92.47
Open Price
92.5
Volume
124,986
Today Low / High
91.77 / 93.74
52 WK Low / High
85.46 / 125.54
Range
87 - 96
BSE
91.94
-0.53 (-0.57%)
Prev Close
92.47
Open Price
93.3
Volume
10,319
Today Low / High
91.8 / 93.3
52 WK Low / High
85.55 / 125.7
Range
87 - 97
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 91.8 (target range: 87 - 96), reflecting a change of -0.67 (-0.72456%). On the BSE, it is listed at 91.94 (target range: 87 - 97), showing a change of -0.53 (-0.57316%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
25 Feb
92.50
-0.76%
24 Feb
94.50
-2.15%
23 Feb
94.05
0.75%
20 Feb
95.35
-1.46%
19 Feb
96.00
-2.58%
18 Feb
96.00
-0.43%
17 Feb
94.85
0.91%
16 Feb
95.47
-0.58%
13 Feb
96.99
-1.57%
12 Feb
99.45
-0.87%
11 Feb
100.70
-1.57%
10 Feb
99.06
1.06%
09 Feb
97.57
1.35%
06 Feb
96.49
0.65%
05 Feb
96.00
1.02%
04 Feb
94.67
1.65%
03 Feb
95.02
-0.37%
02 Feb
92.20
-0.02%
01 Feb
93.40
-1.28%
30 Jan
93.49
-0.60%
29 Jan
93.00
0.06%
28 Jan
91.35
2.24%
Alembic Limited Graph
Alembic Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 91.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 91.94 | 92.86 | 83.57 - 102.15 |
| 93.78 | 75.02 - 112.53 | ||
| 94.70 | 66.29 - 123.11 | ||
| Bearish Scenario | 91.94 | 91.02 | 81.92 - 100.12 |
| 90.10 | 72.08 - 108.12 | ||
| 89.18 | 62.43 - 115.94 |
Overview of Alembic Limited
ISIN
INE426A01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
250,583
Market Cap
23,572,571,810
Last Dividend
2.4
Official Website
IPO Date
2002-07-01
DCF Diff
187.26
DCF
-77
Financial Ratios Every Investor Needs
Stock Dividend of ALEMBICLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-05 | August 05, 25 | 2.4 | 2.4 | 2025-08-05 | 2025-08-14 | |
| 2024-08-05 | August 05, 24 | 2.4 | 2.4 | 2024-08-05 | 2024-09-11 | |
| 2023-08-03 | August 03, 23 | 2.2 | 2.2 | 2023-08-03 | 2023-09-09 | |
| 2022-09-12 | September 12, 22 | 1.8 | 1.8 | 2022-09-13 | 2022-09-23 | |
| 2021-07-29 | July 29, 21 | 0.2 | 0.2 | 2021-07-30 | 2021-08-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 221.89 Cr | 69.16 Cr | 152.73 Cr | 0.6883 | 0.00 Cr | 9.05 Cr | 125.42 Cr | 310.68 Cr | 12.10 | 168.60 Cr | 1.4002 |
| 2024-03-31 | 157.49 Cr | 83.92 Cr | 87.25 Cr | 0.5540 | 0.10 Cr | 6.70 Cr | 49.02 Cr | 268.62 Cr | 10.46 | 111.63 Cr | 1.7057 |
| 2023-03-31 | 118.34 Cr | 48.13 Cr | 70.21 Cr | 0.5933 | 0.66 Cr | 5.51 Cr | 33.61 Cr | 190.65 Cr | 7.42 | 93.99 Cr | 1.6110 |
| 2022-03-31 | 71.37 Cr | 30.92 Cr | 40.45 Cr | 0.5668 | 1.03 Cr | 6.36 Cr | 9.26 Cr | 222.06 Cr | 8.65 | 103.11 Cr | 3.1114 |
| 2021-03-31 | 67.84 Cr | 28.56 Cr | 39.27 Cr | 0.5789 | 0.39 Cr | 3.64 Cr | 7.36 Cr | 342.84 Cr | 13.35 | 21.34 Cr | 5.0539 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2.71 Cr | 2,503.00 Cr | 164.41 Cr | 2,338.5900 Cr | 14.45 Cr | 11.74 Cr | 99.39 Cr | 135.33 Cr | 0.00 Cr | 4.08 Cr | 1,844.95 Cr | 110.4700 Cr |
| 2024-03-31 | 1.26 Cr | 2,328.77 Cr | 143.21 Cr | 2,185.5645 Cr | 9.15 Cr | 7.89 Cr | 92.60 Cr | 131.64 Cr | 0.00 Cr | 4.24 Cr | 1,774.71 Cr | 90.3159 Cr |
| 2023-03-31 | 0.93 Cr | 2,204.58 Cr | 126.55 Cr | 2,078.0328 Cr | 0.00 Cr | -0.93 Cr | 88.61 Cr | 131.96 Cr | 0.00 Cr | 1.81 Cr | 1,899.22 Cr | 83.8105 Cr |
| 2022-03-31 | 1.17 Cr | 2,631.95 Cr | 135.37 Cr | 2,496.5833 Cr | 0.00 Cr | -1.17 Cr | 86.87 Cr | 133.69 Cr | 0.00 Cr | 2.02 Cr | 2,182.05 Cr | 67.7648 Cr |
| 2021-03-31 | 5.89 Cr | 2,408.96 Cr | 111.93 Cr | 2,297.0281 Cr | 0.28 Cr | -5.61 Cr | 54.28 Cr | 139.53 Cr | 0.00 Cr | 1.94 Cr | 2,166.44 Cr | 59.4153 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 86.3700 Cr | -26.5800 Cr | -58.3400 Cr | 35.6000 Cr | 1.4500 Cr | 2.7100 Cr | -50.7700 Cr | 155.5000 Cr | 5.3000 Cr | -61.1700 Cr | -6.7800 Cr |
| 2024-03-31 | 22.6865 Cr | 25.8363 Cr | -48.1936 Cr | -33.6034 Cr | 0.3291 Cr | 1.2609 Cr | -56.2899 Cr | 102.6862 Cr | 9.1490 Cr | -56.2340 Cr | -3.9900 Cr |
| 2023-03-31 | 38.8525 Cr | 7.2960 Cr | -46.3882 Cr | 13.0346 Cr | -0.2396 Cr | 0.9318 Cr | -25.8179 Cr | 86.8000 Cr | 0.0000 Cr | -45.9228 Cr | -1.7400 Cr |
| 2022-03-31 | -17.7469 Cr | 18.8478 Cr | -5.8165 Cr | -53.5601 Cr | -4.7157 Cr | 1.1714 Cr | -35.8132 Cr | 97.8574 Cr | -0.2766 Cr | -5.1508 Cr | -32.5884 Cr |
| 2021-03-31 | -2.1817 Cr | -34.8694 Cr | -15.3620 Cr | -49.6370 Cr | -52.9679 Cr | 5.8871 Cr | -47.4553 Cr | 17.0412 Cr | 0.2766 Cr | -15.2767 Cr | -18.8683 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 74.34 Cr | 39.60 Cr | 34.74 Cr | 0.4673 | 25.44 Cr | 60.13 Cr | 2.34 | 28.88 Cr | 0.8089 |
| 2025-09-30 | 55.86 Cr | 15.84 Cr | 40.02 Cr | 0.7164 | 20.42 Cr | 128.49 Cr | 5.00 | 88.16 Cr | 2.3002 |
| 2025-06-30 | 49.75 Cr | 15.29 Cr | 34.46 Cr | 0.6927 | 16.79 Cr | 61.64 Cr | 2.40 | 23.16 Cr | 1.2390 |
| 2025-03-31 | 60.27 Cr | 17.38 Cr | 42.89 Cr | 0.7116 | 24.57 Cr | 68.45 Cr | 2.67 | 30.29 Cr | 1.1357 |
| 2024-12-31 | 57.92 Cr | 17.00 Cr | 40.92 Cr | 0.7065 | 23.70 Cr | 65.39 Cr | 2.55 | 30.76 Cr | 1.1290 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1.41 Cr | 87.40 Cr | 88.81 Cr | 31.04 Cr | 92.03 Cr | 224.73 Cr | 134.78 Cr | 2,726.89 Cr | 191.09 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 58.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,338.59 Cr |
| 2025-03-31 | 2.71 Cr | 0.46 Cr | 58.28 Cr | 29.97 Cr | 99.39 Cr | 204.87 Cr | 135.33 Cr | 2,503.00 Cr | 164.41 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 42.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,246.43 Cr |
| 2024-09-30 | 1.75 Cr | 44.01 Cr | 45.76 Cr | 43.46 Cr | 97.05 Cr | 199.72 Cr | 131.37 Cr | 2,440.96 Cr | 194.53 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 61.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 68.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 65.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 121.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 55.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2013-09-27 | September 27, 13 | 2:1 |
| 2006-09-26 | September 26, 06 | 5:1 |
| 2004-03-25 | March 25, 04 | 2:1 |
| 2003-12-10 | December 10, 03 | 1083:1000 |
| 1999-07-26 | July 26, 99 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,763.30 | ₹4,230,747,352,601.00 | ₹1,200,917.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,387.50 | ₹1,695,680,554,750.00 | ₹348,445.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,435.00 | ₹1,501,005,526,400.00 | ₹360,000.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,305.00 | ₹1,086,501,487,950.00 | ₹2,296,188.00 |
| Lupin Limited | LUPIN | ₹2,293.00 | ₹1,047,999,599,000.00 | ₹1,104,217.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹918.70 | ₹924,427,166,613.00 | ₹564,622.00 |
| Mankind Pharma Limited | MANKIND | ₹2,165.00 | ₹893,722,980,880.00 | ₹802,350.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,215.20 | ₹705,790,132,270.00 | ₹3,039,195.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,646.00 | ₹675,063,990,000.00 | ₹231,441.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,078.50 | ₹586,554,381,507.00 | ₹455,455.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,075.00 | ₹580,345,825,650.00 | ₹2,096,375.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,523.30 | ₹386,467,635,279.00 | ₹102,381.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹3,019.50 | ₹377,243,116,668.00 | ₹185,673.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,087.90 | ₹335,165,447,241.00 | ₹172,357.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,425.00 | ₹270,140,869,500.00 | ₹90,094.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,387.00 | ₹225,376,638,403.00 | ₹212,895.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,889.00 | ₹222,225,000,000.00 | ₹2,581.00 |
| Eris Lifesciences Limited | ERIS | ₹1,380.40 | ₹188,033,796,336.00 | ₹30,282.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹976.20 | ₹174,847,055,094.00 | ₹5,721,410.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,366.00 | ₹171,484,296,374.00 | ₹27,191.00 |
| Granules India Limited | GRANULES | ₹599.95 | ₹145,589,096,164.00 | ₹775,189.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹736.90 | ₹144,847,366,076.00 | ₹143,344.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹906.00 | ₹143,482,991,688.00 | ₹305,240.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,729.00 | ₹131,424,222,384.00 | ₹21,588.00 |
| Cohance Lifesciences Limited | COHANCE | ₹308.75 | ₹118,117,604,475.00 | ₹467,933.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹912.30 | ₹111,972,052,800.00 | ₹41,727.00 |
| Viyash Scientific Limited | VIYASH | ₹220.00 | ₹95,965,222,980.00 | ₹684,579.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,130.00 | ₹85,154,829,660.00 | ₹7,924.00 |
| Strides Pharma Science Limited | STAR | ₹860.15 | ₹79,282,359,947.00 | ₹85,838.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹479.00 | ₹73,335,885,782.00 | ₹136,599.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹708.95 | ₹64,264,396,246.00 | ₹171,834.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹328.00 | ₹64,150,835,648.00 | ₹194,469.00 |
| FDC Limited | FDC | ₹365.80 | ₹59,555,928,727.00 | ₹46,681.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹129.38 | ₹41,986,603,055.00 | ₹619,352.00 |
| Innova Captab Limited | INNOVACAP | ₹668.00 | ₹38,226,252,572.00 | ₹12,206.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹318.90 | ₹34,749,023,009.00 | ₹32,184.00 |
| Suven Life Sciences Limited | SUVEN | ₹150.24 | ₹34,175,693,760.00 | ₹112,596.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹370.50 | ₹33,815,535,000.00 | ₹60,674.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹635.60 | ₹32,237,063,138.00 | ₹129,617.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,897.80 | ₹31,387,742,667.00 | ₹9,696.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹279.00 | ₹27,978,819,174.00 | ₹39,130.00 |
Key Executives
Associate Vice President of HR
Ambarish Jambhorkar
Gender: male
Year Born:
President of Real Estate Operations
Avaneesh Nath Sharma
Gender: male
Year Born:
Company Secretary & Compliance Officer
Kevalkumar Bharatkumar Thakkar
Gender: male
Year Born:
Chief Financial Officer
Rasesh Shah
Gender: male
Year Born:
MD & Director
Udit C. Amin
Gender: male
Year Born: 1980
MD, Chief Executive Officer & Executive Director
Malika C. Amin
Gender: female
Year Born: 1955
FAQs about Alembic Limited
Who is the CEO of the company?
The CEO is Udit C. Amin.
What is the current market price of the stock?
The current price is ₹91.80.
What is the 52-week price range?
The range is ₹85.46-125.54.
What is the market capitalization of the company?
The market capitalization is ₹2,357.26 crores.
What is the dividend yield?
The dividend yield is 2.61%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 7.40.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Limited (ISIN: INE426A01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,357.26 crores and an average daily volume of 250,583 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.4.